259 related articles for article (PubMed ID: 19775997)
1. Translational research in phase I trials.
Fasolo A; Sessa C
Clin Transl Oncol; 2009 Sep; 11(9):580-8. PubMed ID: 19775997
[TBL] [Abstract][Full Text] [Related]
2. Predictive biomarkers for personalised anti-cancer drug use: discovery to clinical implementation.
Alymani NA; Smith MD; Williams DJ; Petty RD
Eur J Cancer; 2010 Mar; 46(5):869-79. PubMed ID: 20138504
[TBL] [Abstract][Full Text] [Related]
3. Clinical trial designs for targeted agents.
Ma BB; Britten CD; Siu LL
Hematol Oncol Clin North Am; 2002 Oct; 16(5):1287-305. PubMed ID: 12512393
[TBL] [Abstract][Full Text] [Related]
4. Integrating data from the Investigational Medicinal Product Dossier/investigator's brochure. A new tool for translational integration of preclinical effects.
van Gerven J; Cohen A
Br J Clin Pharmacol; 2018 Jul; 84(7):1457-1466. PubMed ID: 29381216
[No Abstract] [Full Text] [Related]
5. Can molecular biomarker-based patient selection in Phase I trials accelerate anticancer drug development?
Carden CP; Sarker D; Postel-Vinay S; Yap TA; Attard G; Banerji U; Garrett MD; Thomas GV; Workman P; Kaye SB; de Bono JS
Drug Discov Today; 2010 Feb; 15(3-4):88-97. PubMed ID: 19961955
[TBL] [Abstract][Full Text] [Related]
6. Targeted agents: how to select the winners in preclinical and early clinical studies?
Goodwin R; Giaccone G; Calvert H; Lobbezoo M; Eisenhauer EA
Eur J Cancer; 2012 Jan; 48(2):170-8. PubMed ID: 22093946
[TBL] [Abstract][Full Text] [Related]
7. Optimizing oncology therapeutics through quantitative translational and clinical pharmacology: challenges and opportunities.
Venkatakrishnan K; Friberg LE; Ouellet D; Mettetal JT; Stein A; Trocóniz IF; Bruno R; Mehrotra N; Gobburu J; Mould DR
Clin Pharmacol Ther; 2015 Jan; 97(1):37-54. PubMed ID: 25670382
[TBL] [Abstract][Full Text] [Related]
8. Recent innovations in the USA National Cancer Institute-sponsored investigator initiated Phase I and II anticancer drug development.
Bando H; Takebe N
Jpn J Clin Oncol; 2015 Nov; 45(11):1001-6. PubMed ID: 26423340
[TBL] [Abstract][Full Text] [Related]
9. Advances in cancer drug discovery - a British association for cancer research meeting.
Westwell AD
IDrugs; 2008 Nov; 11(11):783-6. PubMed ID: 18988118
[TBL] [Abstract][Full Text] [Related]
10. Personalised medicine for cancer: from drug development into clinical practice.
Jain KK
Expert Opin Pharmacother; 2005 Aug; 6(9):1463-76. PubMed ID: 16086635
[TBL] [Abstract][Full Text] [Related]
11. Cooperation needed to optimise cancer drug development.
Mayor S
Lancet; 2004 Mar; 363(9414):1045. PubMed ID: 15065559
[No Abstract] [Full Text] [Related]
12. An overview of the optimal planning, design, and conduct of phase I studies of new therapeutics.
LoRusso PM; Boerner SA; Seymour L
Clin Cancer Res; 2010 Mar; 16(6):1710-8. PubMed ID: 20215546
[TBL] [Abstract][Full Text] [Related]
13. The changing landscape of phase I trials in oncology.
Wong KM; Capasso A; Eckhardt SG
Nat Rev Clin Oncol; 2016 Feb; 13(2):106-17. PubMed ID: 26552953
[TBL] [Abstract][Full Text] [Related]
14. Evidence-based laboratory medicine in oncology drug development: from biomarkers to diagnostics.
Modur V; Hailman E; Barrett JC
Clin Chem; 2013 Jan; 59(1):102-9. PubMed ID: 23034140
[TBL] [Abstract][Full Text] [Related]
15. Advances in translational pharmacological investigations in identifying and validating molecular targets of natural product anticancer agents.
Yu J; Nag SA; Zhang R
Curr Cancer Drug Targets; 2013 Jun; 13(5):596-609. PubMed ID: 23597194
[TBL] [Abstract][Full Text] [Related]
16. New tools for old drugs: Functional genetic screens to optimize current chemotherapy.
Gerhards NM; Rottenberg S
Drug Resist Updat; 2018 Jan; 36():30-46. PubMed ID: 29499836
[TBL] [Abstract][Full Text] [Related]
17. Metabolomics in cancer: a bench-to-bedside intersection.
Claudino WM; Goncalves PH; di Leo A; Philip PA; Sarkar FH
Crit Rev Oncol Hematol; 2012 Oct; 84(1):1-7. PubMed ID: 22429650
[TBL] [Abstract][Full Text] [Related]
18. Alzheimer's disease drug development: translational neuroscience strategies.
Cummings JL; Banks SJ; Gary RK; Kinney JW; Lombardo JM; Walsh RR; Zhong K
CNS Spectr; 2013 Jun; 18(3):128-38. PubMed ID: 23472637
[TBL] [Abstract][Full Text] [Related]
19. Target selection issues in drug discovery and development.
Sausville EA
J Chemother; 2004 Nov; 16 Suppl 4():16-8. PubMed ID: 15688602
[TBL] [Abstract][Full Text] [Related]
20. Nanomedicine: is it lost in translation?
Greish K; Mathur A; Bakhiet M; Taurin S
Ther Deliv; 2018 Mar; 9(4):269-285. PubMed ID: 29495928
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
